This article is more than 5 years old. Information may no longer be current.
Samuel Waxman Cancer Research Foundation to present award
Click Here to Manage Email Alerts
The Samuel Waxman Cancer Research Foundation will present the 2018 David T. Workman Memorial Award to Craig B. Thompson, MD.
The award provides biennial recognition and two-year grant to scientists who develop novel therapies for poorly treatable cancer types.
Thompson, president and CEO of Memorial Sloan Kettering Cancer Center, will be recognized for his leadership role in the development of AG-221 (Celgene/Agios), a therapy for acute myeloid leukemia that blocks the IDH1-2 enzyme’s disruption of normal cell maturation.
“We are excited to celebrate the achievements of Dr. Craig Thompson,” Samuel Waxman, MD, founder and CEO of the Samuel Waxman Cancer Research Foundation, said in a press release. “He played a major role in bringing cancer metabolism into the mainstream by identifying the importance of IDH1-2 mutations in cancer cell differentiation to create a novel therapy. This breakthrough work perfectly embodies the spirit of the David Workman Award.”
Thompson will receive the award on April 30 at the foundation’s Breakthroughs Scientific Symposium.